Online inquiry

IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12999MR)

This product GTTS-WQ12999MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF3R gene. The antibody can be applied in Neutropenia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000760.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1441
UniProt ID Q99062
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12999MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4258MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ8763MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ12106MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ12292MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ1827MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ13549MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ10417MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ3341MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AT-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW